Go Pro
NASDAQ:HKPD

Hong Kong Pharma Digital Technology (HKPD) Stock Price, News & Analysis

Hong Kong Pharma Digital Technology logo
$0.42 +0.00 (+0.24%)
As of 01:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Hong Kong Pharma Digital Technology Stock (NASDAQ:HKPD)

Advanced

Key Stats

Today's Range
$0.40
$0.42
50-Day Range
$0.33
$0.50
52-Week Range
$0.31
$2.58
Volume
57,422 shs
Average Volume
358,937 shs
Market Capitalization
$4.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division. Based in Hong Kong, Joint Cross Border has established itself as a leading provider of third-party supply chain services in Mainland China’s OTC pharmaceutical cross-border e-commerce market. According to the F&S Report, we ranked first in this sector by revenue in 2022. Through our engagement with OTC pharmaceutical suppliers, logistics companies, and merchants who operate stores on Chinese e-commerce platforms, Joint Cross Border offers a convenient one-stop solution for Mainland Chinese customers who wish to access OTC pharmaceutical products outside Mainland China. Joint Cross Border’s offering includes a comprehensive array of services, such as pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting OTC pharmaceutical products to the Hong Kong Department of Health (“HKDOH”), obtaining import and export permits and clearances, storing products at warehouses, packaging, and arranging for logistics and end-to-end delivery services for consumers. The regulations and policies governing cross-border transportation of OTC pharmaceutical products vary from country to country. We believe that the traditional supply chain is inefficient in navigating the intricate regulatory landscape and thus unable to meet the significant and growing demand for overseas OTC pharmaceuticals by Mainland Chinese consumers. To capture this opportunity, Joint Cross Border offers its clients a suite of supply chain solutions to address the unique needs of handling cross-border OTC pharmaceutical products. We believe our advanced technological capabilities, vast experience in the OTC pharmaceutical supply chain service industry, and e-commerce insights can further entrench our position as an ever more important player in Mainland China’s OTC pharmaceutical cross-border e-commerce market. Our main customers are (i) e-commerce platform logistics partners like Hangzhou Cainiao Supply Chain Management Co., Ltd. (“CaiNiao”) who hire our supply chain services related to cross-border OTC pharmaceutical products and (ii) merchants on established Chinese e-commerce platforms such as Tmall, Meituan, Pinduoduo, JD.com, Xiaohongshu, and Youzan to offer popular OTC pharmaceutical products sourced from Hong Kong, Taiwan, Japan, and certain European countries like the United Kingdom and German. As of the date of this prospectus, our system has cataloged more than 6,000 stock keeping units (“SKUs”), including over 4,000 HKDOH-enlisted OTC SKUs. The OTC pharmaceutical products we manage or distribute include traditional OTC Chinese medicine manufactured in Hong Kong and outside China, and non-Chinese OTC medicine registered in Hong Kong and outside China. While over 90% of the products we deal with are OTC pharmaceutical products on average, our portfolio also includes non-pharmaceutical items such as health supplements. We have received notable recognitions, including membership in The H.K. Medicine Dealers’ Guild, The Pharmaceutical Distributors Association of Hong Kong, and China Medical Pharmaceutical Material Association. Our principal executive offices are located at Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon, Hong Kong. Hong Kong Pharma’s registered office is currently located at the office of Harneys Fiduciary (Cayman) Limited, 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands, which may be changed from time to time at the discretion of directors. Hong Kong Pharma’s agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168.

Hong Kong Pharma Digital Technology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

HKPD MarketRank™: 

Hong Kong Pharma Digital Technology scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Hong Kong Pharma Digital Technology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Hong Kong Pharma Digital Technology has only been the subject of 1 research reports in the past 90 days.

  • Read more about Hong Kong Pharma Digital Technology's stock forecast and price target.
  • Price to Book Value per Share Ratio

    Hong Kong Pharma Digital Technology has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.25% of the float of Hong Kong Pharma Digital Technology has been sold short.
  • Short Interest Ratio / Days to Cover

    Hong Kong Pharma Digital Technology has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Hong Kong Pharma Digital Technology has recently increased by 161.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Hong Kong Pharma Digital Technology does not currently pay a dividend.

  • Dividend Growth

    Hong Kong Pharma Digital Technology does not have a long track record of dividend growth.

  • News Sentiment

    Hong Kong Pharma Digital Technology has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Hong Kong Pharma Digital Technology this week, compared to 1 article on an average week.
Receive HKPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hong Kong Pharma Digital Technology and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HKPD Stock News Headlines

Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
See More Headlines

HKPD Stock Analysis - Frequently Asked Questions

Hong Kong Pharma Digital Technology's stock was trading at $0.8244 on January 1st, 2026. Since then, HKPD stock has decreased by 48.9% and is now trading at $0.4210.

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) issued its earnings results on Friday, August, 7th. The company reported ($0.04) earnings per share (EPS) for the quarter. The company earned $3.15 million during the quarter.

Hong Kong Pharma Digital Technology (HKPD) raised $7 million in an initial public offering on Wednesday, January 15th 2025. The company issued 1,403,685 shares at $4.00-$6.00 per share.

Shares of HKPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/07/2026
Today
8/14/2026
Fiscal Year End
3/31/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Distributors
Current Symbol
NASDAQ:HKPD
CIK
2007702
Fax
N/A
Employees
19
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$13.43 million
Price / Sales
0.34
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.45 per share
Price / Book
0.91

Miscellaneous

Outstanding Shares
11,000,000
Free Float
N/A
Market Cap
$4.52 million
Optionable
N/A
Beta
2.33
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:HKPD) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners